AxoGen Q4 Earnings Call Highlights

Core Insights - AxoGen reported a significant financial inflection point, driven by the FDA approval of the Avance biologics license application (BLA) and accelerating adoption of its nerve repair algorithm [5][7] Financial Performance - Fourth-quarter revenue reached $59.9 million, marking a 21.3% increase year-over-year, while full-year revenue rose 20.2% to $225.2 million [4][8] - Gross margin for the fourth quarter was 74.1%, down from 76.1% a year earlier, and full-year gross margin was 74.3%, compared to 75.8% in 2024 [2] - The company reported a fourth-quarter net loss of $13.2 million, or $0.28 per share, compared to a net income of $0.5 million, or $0.01 per share, in the prior-year quarter [9] Strategic Initiatives - Management emphasized six strategic priorities for market development and commercial expansion across various medical fields, including extremities and breast [12] - The company plans to expand its commercial organization, with new hires expected to reach independence within six to nine months [15] Market Dynamics - The FDA BLA approval for Avance is expected to enhance payer coverage, with commercial coverage projected to exceed 65% after 2025 [7][21] - Approximately 19.8 million additional lives gained coverage in 2025, indicating a positive trend in reimbursement dynamics [21] 2026 Outlook - AxoGen guided for at least 18% revenue growth in 2026, implying revenue of at least $265.7 million, with a gross margin target of 74% to 76% [6][24] - The company anticipates being free-cash-flow positive for the full year of 2026, despite expected higher cash burn in the first quarter [24]